Filing Details
- Accession Number:
- 0001635236-23-000003
- Form Type:
- 13G Filing
- Publication Date:
- 2023-02-09 19:00:00
- Filed By:
- Nine Ten Partners
- Company:
- Iradimed Corp (NASDAQ:IRMD)
- Filing Date:
- 2023-02-10
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Nine Ten Capital Management | 781,766 | 0 | 781,766 | 0 | 781,766 | 6.2% |
Nine Ten Partners | 781,766 | 0 | 781,766 | 0 | 781,766 | 6.2% |
Russell Mollen | 781,766 | 0 | 781,766 | 0 | 781,766 | 6.2% |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Amendment No.: 3 Name of Issuer: Iradimed Corp Title of Class of Securities: Common CUSIP Number: 46266A109 December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: /X/ Rule 13d-l(b) / / Rule 13d-l(c) / / Rule 13d-l(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP Number: 46266A109 1. Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person Nine Ten Capital Management LLC - IRS # 46-5220958 2. Check the Appropriate Box if a Member of a Group a. / / b. // 3. SEC Use Only 4. Citizenship or Place of Organization Evanston, IL 5. Sole Voting Power: 781,766 6. Shared Voting Power: 0 7. Sole Dispositive Power: 781,766 8. Shared Dispositive Power: 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person: 781,766 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares / / 11. Percent of Class Represented by Amount in Row (9): 6.2% 12. Type of Reporting Person: IA -2- CUSIP Number: 46266A109 1. Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person Nine Ten Partners LP - IRS # 46-5301261 2. Check the Appropriate Box if a Member of a Group a. / / b. // 3. SEC Use Only 4. Citizenship or Place of Organization United States Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power: 781,766 6. Shared Voting Power: 0 7. Sole Dispositive Power: 781,766 8. Shared Dispositive Power: 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person: 781,766 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares / / 11. Percent of Class Represented by Amount in Row (9): 6.2% 12. Type of Reporting Person: PN -3- Item 1(a) Name of Issuer: Iradimed Corp (b) Address of Issuer's Principal Executive Offices: 1025 WILLA SPRINGS DR. WINTER SPRINGS FL 32708 Item 2(a) - (c). Name, Principal Business Address, and Citizenship of Persons Filing: (a) Name of Person Filing Nine Ten Capital Management LLC (b) Address of the Principal Office or, if none, residence 1603 Orrington Ave, Ste 1650 Evanston, IL 60201 (c) Citizenship United States (d) Title of Class of Securities: Common (e) CUSIP Number: 46266A109 Item 3. This statement is filed pursuant to Rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: / / Broker or Dealer registered under Section 15 of the Act. /x/ Investment Adviser in accordance with Section 240.13d-1 (b)(1)(ii)(E) Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.